MA5-15417

antibody from Invitrogen Antibodies

Targeting: PPARG NR1C3, PPARG1, PPARG2, PPARgamma

Western blot (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-15417

Provider

Invitrogen Antibodies

Product name

PPAR gamma Monoclonal Antibody (3A4A9, 1E6A1)

Antibody type

Monoclonal

Antigen

Purifed from natural sources

Description

MA5-15417 targets PPARG in WB applications and shows reactivity with Human samples.

Antibody clone number

3A4A9, 1E6A1

Concentration

Conc. Not Determined

References

Submitted references

Characterization of a pluripotent stem cell-derived matrix with powerful osteoregenerative capabilities.

McNeill EP, Zeitouni S, Pan S, Haskell A, Cesarek M, Tahan D, Clough BH, Krause U, Dobson LK, Garcia M, Kung C, Zhao Q, Saunders WB, Liu F, Kaunas R, Gregory CA
Nature communications 2020 Jun 15;11(1):3025

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of PPARG using a PPARG monoclonal antibody (Product # MA5-15417) against a truncated PPARG-His recombinant protein (1) and full-length PPARG (aa1-477) transfected CHO-K1 cell lysate (2).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 2 Osteogenesis by ihMSCs is regulated by the cWnt/PPARgamma axis and PPARgamma inhibition increases osteogenesis and matrix productivity. a immunoblotting of ihMSC extracts (replicates of 3) for GSK3beta, beta-catenin, and PPARgamma isoforms in the presence and absence of osteogenic stimulus. ""Supernatant"" and ""Pellet"" represent cytosolic and insoluble extracts respectively. b Densitometry measurements of images in a . c GW9662 exposure under osteogenic conditions causes further upregulation of insoluble beta-catenin and downregulation of soluble GSK3beta. d Densitometry measurements of images in c . e GW9662 exposure under osteogenic conditions causes upregulation of the osteogenic biomarker ALP in ihMSCs. f Culture conditions as e , but mineralization assays with ARS. Representative ARS-stained monolayers are presented (left) with quantification of staining (right). bdl below detectable limits. g Osteogenically enhanced ihMSCs on monolayers generate higher yields of ECM by mass when treated with GW9662. h Protein content in ECM from OEihMSCs and bone marrow-derived OEhMSCs. i Calcium content in ECM recovered from OEihMSCs and BM-OEhMSCs. j GAG content in ECM recovered from OEihMSCs and BM-OEhMSCs treated with GW9662. Statistics: For panels b and d , data presented with means and SD and analyzed by two-tailed Student's t -test. For panels b , d , g - j , n = 3; for f , n = 5; for e , n = 4. Source data are provided as a Source Data file. For panels e - j , data pres